Skip to menu Skip to content Skip to footer
News

Gut reaction linked to type 1 diabetes

13 August 2018
Decorative

Understanding the link between diabetes and the gut could lead to the development of new therapies to delay the onset of type 1 diabetes, according to University of Queensland researchers.

UQ Diamantina Institute Senior Research Fellow Dr Emma Hamilton-Williams said a change in microorganisms in the gut could help predict and monitor the progression of the disease.  

“Type 1 diabetes is caused by an immune attack on the pancreas,” she said.

“While there has been a suspected link between gut bacteria and disease progression, a direct relationship between pancreas function and gut bacteria hasn’t been shown until now.

“By studying the stool samples of participants, we found that changes in gut bacteria weren’t just a side effect of the disease, but are likely related to disease progression.

“Seeing the same characteristics in recently diagnosed patients and undiagnosed high-risk relatives means these proteins may be used to predict a future diabetes diagnosis.”

“Understanding what pathways lead patients to develop type 1 diabetes is key to developing new treatment strategies and accurately measuring the success of clinical trials.

“We would like to conduct a study where we monitor subjects before and after diagnosis to confirm whether the proteins we indentified predict disease progression.

“The team is now involved in clinically trialling a specialised dietary supplement to target the gut microbiota in patients with type 1 diabetes.

“We hope that this treatment reverses the disease-associated changes we found in our study.”

The study was funded by Juvenile Diabetes Research Foundation International and is published in Diabetes Care (https://doi.org/10.2337/dc18-0777).

Media: Dr Dr Emma Hamilton-Williams, e.hamiltonwilliams@uq.edu.au, +61 7 3443 6989; Faculty of Medicine, med.media@uq.edu.au, +61 7 3365 5118.

Related articles

Close-up photo of a pair of hands holding a Wegovy injection pen, with the medication package on a light-coloured surface
Analysis

Would subsidising weight loss drugs make health care fairer?

GLP-1 medicines such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity, but access to them in Australia increasingly depends on something much less medical: whether you can afford them.
20 October 2026
Woman wearing a medical mask and grey t-shirt getting a vaccination from a nurse wearing blue surgical gloves.

Vaccination has little impact on post-COVID smell and taste issues

Researchers examining whether COVID-19 vaccination affects persistent smell or taste problems after contracting the virus have found that, in most cases, it does not.
20 October 2026

Media contact

Subscribe to UQ News

Get the latest from our newsroom.